<clinical_study>
<study_id>
<org_name>
  Lilly
</org_name>
<org_full_name>
  Eli Lilly and Company
</org_full_name>
<org_study_id>
  4015
</org_study_id>
<secondary_id>
  B9E-MC-JHQS
</secondary_id>
<nct_id>
  NCT00191100
</nct_id>
</study_id>
<is_fda_regulated>
  Yes
</is_fda_regulated>
<is_section_801>
  Yes
</is_section_801>
<delayed_posting>
  No
</delayed_posting>
<brief_title>
<textblock>
  Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
</textblock>
</brief_title>
<official_title>
<textblock>
  Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA
</textblock>
</official_title>
<study_sponsor>
<lead_sponsor>
<agency>
  Eli Lilly and Company
</agency>
</lead_sponsor>
</study_sponsor>
<resp_party>
<name_title>
  Chief Medical Officer
</name_title>
<organization>
  Eli Lilly
</organization>
</resp_party>
<oversight_info>
<regulatory_authority>
  Mexico: National Institute of Public Health, Health Secretariat
</regulatory_authority>
</oversight_info>
<brief_summary>
<textblock>
  The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy
</textblock>
</brief_summary>
<detailed_descr>
<textblock>
</textblock>
</detailed_descr>
<status_block>
<status>
  Completed
</status>
<date>
  2008-10
</date>
</status_block>
<start_date>
<date>
  2002-05
</date>
</start_date>
<end_date>
<date>
</date>
</end_date>
<last_follow_up_date
 type="Actual"
>
<date>
2008-04 
</date>
</last_follow_up_date>
<primary_compl_date
 type="Actual"
>
<date>
2008-04 
</date>
</primary_compl_date>
<phase_block>
<phase>
  Phase 3
</phase>
</phase_block>
<study_type>
  Interventional
</study_type>
<design>
  Treatment
</design>
<design>
  Randomized
</design>
<design>
  Open Label
</design>
<design>
  Active Control
</design>
<design>
  Parallel Assignment
</design>
<design>
  Efficacy Study
</design>
<number_of_arms>
  2
</number_of_arms>
<primary_outcome>
<measure>
  Progression free survival
</measure>
<time_frame>
  3 years
</time_frame>
<safety_issue>
  No
</safety_issue>
</primary_outcome>
<secondary_outcome>
<measure>
  Time to progressive disease
</measure>
<time_frame>
  Baseline to measured progressive disease
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Local failure rate.
</measure>
<time_frame>
  Baseline to measured local  progressive disease
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Tumor response rate.
</measure>
<time_frame>
  Baseline to measured progressive disease
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Safety and Adverse Events
</measure>
<time_frame>
  Every cycle
</time_frame>
<safety_issue>
  Yes
</safety_issue>
</secondary_outcome>
<secondary_outcome>
<measure>
  Overall survival
</measure>
<time_frame>
  Baseline to date of death from any cause
</time_frame>
<safety_issue>
  No
</safety_issue>
</secondary_outcome>
<enrollment
 type="Actual"
>
  516
</enrollment>
<condition>
  Cancer of Cervix
</condition>
<arm_group>
<arm_group_label>
  1
</arm_group_label>
<arm_type>
  Experimental
</arm_type>
<description>
<textblock>
  Cisplatin, 40 mg/m2, QW, IV, 6 weeks and
  Gemcitabine 125 mg/m2, QW, IV, 6 weeks and
  Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
 
 
 
  Brachytherapy, 30-35 Gy over 1 week
 
  Two week rest period with no chemotherapy or radiation
 
  Cisplatin, 50 mg/m2, IV, day 1 of 21 day cycle for two 21-day cycles and
  Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
</textblock>
</description>
</arm_group>
<arm_group>
<arm_group_label>
  2
</arm_group_label>
<arm_type>
  Active Comparator
</arm_type>
<description>
<textblock>
  Cisplatin, 40 mg/m2, QW, IV, 6 weeks and
  Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
 
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
</arm_group>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Gemcitabine
</primary_name>
<description>
<textblock>
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<other_name>
  LY188011
</other_name>
<other_name>
  Gemzar
</other_name>
</intervention>
<intervention>
<intervent_type>
  Drug
</intervent_type>
<primary_name>
  Cisplatin
</primary_name>
<description>
<textblock>
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<arm_group_label>
  2
</arm_group_label>
</intervention>
<intervention>
<intervent_type>
  Radiation
</intervent_type>
<primary_name>
  Brachytherapy
</primary_name>
<description>
<textblock>
  Brachytherapy, 30-35 Gy over 1 week
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<arm_group_label>
  2
</arm_group_label>
</intervention>
<intervention>
<intervent_type>
  Radiation
</intervent_type>
<primary_name>
  Pelvic radiation
</primary_name>
<description>
<textblock>
  Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
</textblock>
</description>
<arm_group_label>
  1
</arm_group_label>
<arm_group_label>
  2
</arm_group_label>
</intervention>
<eligibility>
<criteria>
<textblock>
  Inclusion Criteria:
    - diagnosed with cancer of cervix
    - tumor that can be measured 
    - no previous treatment with chemotherapy or radiation for this cancer
    - able to give written consent
    - willing and able to participate in the study, both during the active treatment and the follow-up period.
 
  Exclusion Criteria:
    - impairment such as hearing loss from prior cisplatin therapy
    - damage to nerves such as being unable to distinguish hot and cold to touch
    - used other experimental medication in past 30 days
    - lab test results are not within the limits required for this study
    - pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of birth control.
</textblock>
</criteria>
<healthy_volunteers>
  No
</healthy_volunteers>
<gender>
  Female
</gender>
<minimum_age>
  18 Years
</minimum_age>
<maximum_age>
  70 Years
</maximum_age>
</eligibility>
<investigator>
<role>
  Study Director
</role>
<name>
  Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
</name>
<affiliation>
<agency>
  Eli Lilly
</agency>
</affiliation>
</investigator>
<contact>
<name>
  There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
</name>
<phone>
  1-317-615-4559
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Buenos Aires
</city>
<state>
</state>
<zip>
</zip>
<country>
  Argentina
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Sarajevo
</city>
<state>
</state>
<zip>
</zip>
<country>
  Bosnia and Herzegovina
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Mumbai
</city>
<state>
</state>
<zip>
</zip>
<country>
  India
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Mexico City
</city>
<state>
</state>
<zip>
</zip>
<country>
  Mexico
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Karachi
</city>
<state>
</state>
<zip>
</zip>
<country>
  Pakistan
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Lima
</city>
<state>
</state>
<zip>
</zip>
<country>
  Peru
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<location>
<facility>
<name>
  For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
</name>
<address>
<city>
  Bangkok
</city>
<state>
</state>
<zip>
</zip>
<country>
  Thailand
</country>
</address>
</facility>
<status>
  Active, not recruiting
</status>
<contact>
<name>
  Eli Lilly
</name>
<phone>
</phone>
<phone_ext>
</phone_ext>
<email>
</email>
</contact>
</location>
<see_also>
<annotation>
<textblock>
  Lilly Clinical Trial Registry
</textblock>
</annotation>
<url>
  http://www.lillytrials.com
</url>
</see_also>
<initial_release_date>
  2005-09-12
</initial_release_date>
<last_release_date>
2008-10-30 
</last_release_date>
<init_results_release_date>
</init_results_release_date>
</clinical_study>
